{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,11]],"date-time":"2026-10-11T13:38:38Z","timestamp":1791725918944,"version":"4.3.4"},"reference-count":31,"publisher":"BMJ","issue":"12","license":[{"start":{"date-parts":[[2024,12,4]],"date-time":"2024-12-04T00:00:00Z","timestamp":1733270400000},"content-version":"unspecified","delay-in-days":3,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"GSK","award":["217615"],"award-info":[{"award-number":["217615"]}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Open"],"accepted":{"date-parts":[[2024,10,31]]},"published-print":{"date-parts":[[2024,12]]},"abstract":"<jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>To evaluate and compare medication adherence and persistence for patients newly initiating single-inhaler triple therapy (SITT) and multiple-inhaler triple therapy (MITT) for chronic obstructive pulmonary disease (COPD) in Japan.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Design<\/jats:title>\n                    <jats:p>Retrospective, new-user, active comparator, observational cohort study using inverse probability of treatment weighting.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Setting<\/jats:title>\n                    <jats:p>Health insurance claims data from the Medical Data Vision Co., Ltd, hospital claims database.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Participants<\/jats:title>\n                    <jats:p>Adults diagnosed with COPD at age \u226540 years newly initiating MITT or SITT (fluticasone furoate\/umeclidinium\/vilanterol (FF\/UMEC\/VI) or formoterol fumarate\/budesonide\/glycopyrronium) from 1 September 2019 to 31 July 2021.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Primary and secondary outcome measures<\/jats:title>\n                    <jats:p>The primary outcome was medication adherence compared between patients using SITT and MITT, assessed by the proportion of days covered \u226580%. Secondary outcomes included medication persistence (time from index treatment initiation to discontinuation) compared between patients using SITT and MITT and medication adherence compared before and after the switch in a subgroup of patients switching from MITT to SITT.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>We included 2575 MITT and 2962 SITT users with similar baseline characteristics following weighting. The proportion of adherent patients was significantly greater for SITT versus MITT users at 6 months (19.7% vs 10.2%, p&lt;0.0001), 12 months (6.0% vs 3.8%, p=0.0009) and 18 months (3.8% vs 1.4%, p&lt;0.0001) post-index. Median persistence was also significantly higher for SITT versus MITT users (2.0 vs 1.0 months, p&lt;0.001). Comparing specific SITT versus MITT, the proportion of adherent patients at each time point and median persistence was greater for FF\/UMEC\/VI. In patients switching from MITT to SITT (n=688), the proportion of adherent patients increased postswitch at the class level and for FF\/UMEC\/VI specifically.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Patients with COPD in Japan who were newly initiating SITT had greater medication adherence and persistence compared with those on MITT up to 18 months following initiation.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/bmjopen-2023-080864","type":"journal-article","created":{"date-parts":[[2024,12,4]],"date-time":"2024-12-04T20:45:24Z","timestamp":1733345124000},"page":"e080864","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":11,"title":["Comparative adherence and persistence of single-inhaler and multiple-inhaler triple therapies among patients with chronic obstructive pulmonary disease in Japan: a retrospective cohort study"],"prefix":"10.1136","volume":"14","author":[{"given":"Sandra","family":"Jok\u0161ait\u0117","sequence":"first","affiliation":[{"name":"Value Evidence and Outcomes, R&D Global Medical, GlaxoSmithKline, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Wood","sequence":"additional","affiliation":[{"name":"Real-world Evidence, Adelphi Real World, Bollington, Cheshire, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Afisi","family":"Ismaila","sequence":"additional","affiliation":[{"name":"Value Evidence and Outcomes, R&D Global Medical, GlaxoSmithKline, Collegeville, Pennsylvania, USA"},{"name":"Department of Health Research Methods, Evidence, and Impact, McMaster University, Hamilton, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucinda","family":"Camidge","sequence":"additional","affiliation":[{"name":"Real-world Evidence, Adelphi Real World, Bollington, Cheshire, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akiko","family":"Mizukami","sequence":"additional","affiliation":[{"name":"Value Evidence and Outcomes, Japan Medical and Development, GlaxoSmithKline, Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandrosz","family":"Czira","sequence":"additional","affiliation":[{"name":"Value Evidence and Outcomes, R&D Global Medical, GlaxoSmithKline, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olivia","family":"Massey","sequence":"additional","affiliation":[{"name":"Real-world Evidence, Adelphi Real World, Bollington, Cheshire, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masao","family":"Yarita","sequence":"additional","affiliation":[{"name":"Value Evidence and Outcomes, Japan Medical and Development, GlaxoSmithKline, Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chris","family":"Compton","sequence":"additional","affiliation":[{"name":"Global Medical, GlaxoSmithKline, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rad","family":"Siddiqui","sequence":"additional","affiliation":[{"name":"Real-world Evidence, Adelphi Real World, Bollington, Cheshire, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Jennison","sequence":"additional","affiliation":[{"name":"Real-world Evidence, Adelphi Real World, Bollington, Cheshire, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takeo","family":"Ishii","sequence":"additional","affiliation":[{"name":"Value Evidence and Outcomes, Japan Medical and Development, GlaxoSmithKline, Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenichi","family":"Hashimoto","sequence":"additional","affiliation":[{"name":"Value Evidence and Outcomes, Japan Medical and Development, GlaxoSmithKline, Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4279-1624","authenticated-orcid":false,"given":"Kieran J","family":"Rothnie","sequence":"additional","affiliation":[{"name":"Value Evidence and Outcomes, R&D Global Medical, GlaxoSmithKline, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2024,12,4]]},"reference":[{"key":"2025120519343789000_14.12.e080864.1","doi-asserted-by":"crossref","first-page":"3459","DOI":"10.2147\/COPD.S165187","article-title":"Understanding low COPD exacerbation rates in Japan: a review and comparison with other countries","volume":"13","author":"Ishii","year":"2018","journal-title":"Int J Chron Obstruct Pulmon Dis"},{"key":"2025120519343789000_14.12.e080864.2","doi-asserted-by":"crossref","first-page":"3878","DOI":"10.21037\/jtd-20-2263","article-title":"Narrative review of current COPD status in Japan","volume":"13","author":"Tanabe","year":"2021","journal-title":"J Thorac Dis"},{"key":"2025120519343789000_14.12.e080864.3","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2018-023673","article-title":"Trends in the prevalence of airflow limitation in a general Japanese population: two serial cross-sectional surveys from the Hisayama Study","volume":"9","author":"Ogata","year":"2019","journal-title":"BMJ Open"},{"key":"2025120519343789000_14.12.e080864.4","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.resinv.2014.08.002","article-title":"Prevalence of asthma with airflow limitation, COPD, and COPD with variable airflow limitation in older subjects in a general Japanese population: the Hisayama Study","volume":"53","author":"Matsumoto","year":"2015","journal-title":"Respir Investig"},{"key":"2025120519343789000_14.12.e080864.5","doi-asserted-by":"publisher","DOI":"10.2169\/internalmedicine.49.3364"},{"key":"2025120519343789000_14.12.e080864.6","doi-asserted-by":"publisher","DOI":"10.1111\/j.1440-1843.2004.00637.x"},{"key":"2025120519343789000_14.12.e080864.7","unstructured":"Japanese Respiratory Society . Guidelines for COPD (chronic obstructive pulmonary disease) diagnosis and treatment (6th edition). 2022. Available: https:\/\/www.jrs.or.jp\/publication\/jrs_guidelines\/20220512084311.html [Accessed 08 Sep 2023]."},{"key":"2025120519343789000_14.12.e080864.8","doi-asserted-by":"crossref","DOI":"10.3390\/diagnostics11071153","article-title":"COPD Guidelines in the Asia-Pacific Regions: Similarities and Differences","volume":"11","author":"Cheng","year":"2021","journal-title":"Diagnostics (Basel)"},{"key":"2025120519343789000_14.12.e080864.9","unstructured":"Global Initiative for Chronic Obstructive Lung Disease . Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease (2023 report). 2023."},{"key":"2025120519343789000_14.12.e080864.10","doi-asserted-by":"crossref","DOI":"10.1183\/23120541.00950-2020","article-title":"INTREPID: single- versus multiple-inhaler triple therapy for COPD in usual clinical practice","volume":"7","author":"Halpin","year":"2021","journal-title":"ERJ Open Res"},{"key":"2025120519343789000_14.12.e080864.11","doi-asserted-by":"crossref","first-page":"343","DOI":"10.2147\/COPD.S184653","article-title":"Medication adherence and persistence in chronic obstructive pulmonary disease patients receiving triple therapy in a USA commercially insured population","volume":"14","author":"Bogart","year":"2019","journal-title":"Int J Chron Obstruct Pulmon Dis"},{"key":"2025120519343789000_14.12.e080864.12","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1016\/j.alit.2016.10.008","article-title":"Poor pharmacological adherence to inhaled medicines compared with oral medicines in Japanese patients with asthma and chronic obstructive pulmonary disease","volume":"66","author":"Imamura","year":"2017","journal-title":"Allergol Int"},{"key":"2025120519343789000_14.12.e080864.13","doi-asserted-by":"crossref","first-page":"1427","DOI":"10.1185\/03007995.2014.908828","article-title":"Impact of adherence to treatment with tiotropium and fluticasone propionate\/salmeterol in chronic obstructive pulmonary diseases patients","volume":"30","author":"Ismaila","year":"2014","journal-title":"Curr Med Res Opin"},{"key":"2025120519343789000_14.12.e080864.14","doi-asserted-by":"publisher","DOI":"10.1136\/thx.2009.113662"},{"key":"2025120519343789000_14.12.e080864.15","doi-asserted-by":"publisher","DOI":"10.1016\/j.rmed.2013.09.021"},{"key":"2025120519343789000_14.12.e080864.16","doi-asserted-by":"publisher","DOI":"10.1016\/j.rmed.2010.09.006"},{"key":"2025120519343789000_14.12.e080864.17","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.rmed.2017.06.007","article-title":"Adherence to COPD treatment: Myth and reality","volume":"129","author":"Rogliani","year":"2017","journal-title":"Respir Med"},{"key":"2025120519343789000_14.12.e080864.18","unstructured":"Pharmaceuticals and Medical Devices Agency . List of approved products - new drugs approved in FY 2018. 2018. Available: https:\/\/www.pmda.go.jp\/files\/000235288.pdf [Accessed 08 Sep 2023]."},{"key":"2025120519343789000_14.12.e080864.19","unstructured":"Pharmaceuticals and Medical Devices Agency . List of approved products - new drugs approved in FY 2019. 2019. Available: https:\/\/www.pmda.go.jp\/files\/000235289.pdf [Accessed 08 Sep 2023]."},{"key":"2025120519343789000_14.12.e080864.20","doi-asserted-by":"publisher","DOI":"10.1016\/j.rmed.2022.106807"},{"key":"2025120519343789000_14.12.e080864.21","doi-asserted-by":"crossref","first-page":"2417","DOI":"10.2147\/COPD.S370540","article-title":"Comparative Adherence and Persistence of Single- and Multiple-Inhaler Triple Therapies Among Patients with Chronic Obstructive Pulmonary Disease in an English Real-World Primary Care Setting","volume":"17","author":"Halpin","year":"2022","journal-title":"Int J Chron Obstruct Pulmon Dis"},{"key":"2025120519343789000_14.12.e080864.22","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/j.resinv.2015.05.005","article-title":"The chronic obstructive pulmonary disease comorbidity spectrum in Japan differs from that in western countries","volume":"53","author":"Takahashi","year":"2015","journal-title":"Respir Investig"},{"key":"2025120519343789000_14.12.e080864.23","unstructured":"MDV EBM insight . MDV database overview. 2023. Available: https:\/\/en.mdv.co.jp\/about-mdv-database\/mdv-database-overview\/ [Accessed 27 Jun 2023]."},{"key":"2025120519343789000_14.12.e080864.24","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1007\/s40801-022-00296-5","article-title":"Context and Considerations for Use of Two Japanese Real-World Databases in Japan: Medical Data Vision and Japanese Medical Data Center","volume":"9","author":"Laurent","year":"2022","journal-title":"Drugs Real World Outcomes"},{"key":"2025120519343789000_14.12.e080864.25","doi-asserted-by":"crossref","first-page":"2135","DOI":"10.2147\/PPA.S268499","article-title":"Impact of Medication Regimen Simplification on Medication Adherence and Clinical Outcomes in Patients with Long-Term Medical Conditions","volume":"14","author":"Elnaem","year":"2020","journal-title":"Patient Prefer Adherence"},{"key":"2025120519343789000_14.12.e080864.26","doi-asserted-by":"crossref","DOI":"10.1186\/s12890-022-01892-5","article-title":"Understanding barriers to and strategies for medication adherence in COPD: a qualitative study","volume":"22","author":"O\u2019Toole","year":"2022","journal-title":"BMC Pulm Med"},{"key":"2025120519343789000_14.12.e080864.27","doi-asserted-by":"crossref","first-page":"486","DOI":"10.3111\/13696998.2011.594123","article-title":"Therapy persistence and adherence in patients with chronic obstructive pulmonary disease: multiple versus single long-acting maintenance inhalers","volume":"14","author":"Yu","year":"2011","journal-title":"J Med Econ"},{"key":"2025120519343789000_14.12.e080864.28","first-page":"25","article-title":"Maximizing Adherence and Gaining New Information For Your Chronic Obstructive Pulmonary Disease (MAGNIFY COPD): Study Protocol for the Pragmatic, Cluster Randomized Trial Evaluating the Impact of Dual Bronchodilator with Add-On Sensor and Electronic Monitoring on Clinical Outcomes","volume":"12","author":"Price","year":"2021","journal-title":"Pragmat Obs Res"},{"key":"2025120519343789000_14.12.e080864.29","unstructured":"Japanese Respiratory Society . The JRS Guidelines for the Management of Chronic Obstructive Pulmonary Disease. 5th edn. Tokyo: Medical Review, 2018."},{"key":"2025120519343789000_14.12.e080864.30","doi-asserted-by":"crossref","first-page":"391","DOI":"10.2147\/COPD.S173901","article-title":"When to use single-inhaler triple therapy in COPD: a practical approach for primary care health care professionals","volume":"14","author":"Gaduzo","year":"2019","journal-title":"Int J Chron Obstruct Pulmon Dis"},{"key":"2025120519343789000_14.12.e080864.31","doi-asserted-by":"crossref","first-page":"175","DOI":"10.2169\/internalmedicine.0488-17","article-title":"Differences in Adherence Barriers to Inhaled Medicines between Japanese Patients with Chronic Obstructive Pulmonary Disease and Asthma Evaluated using the \u201cAdherence Starts with Knowledge 20\u201d (ASK-20) Questionnaire","volume":"58","author":"Toyama","year":"2019","journal-title":"Intern Med"}],"container-title":["BMJ Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjopen-2023-080864","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,6]],"date-time":"2025-12-06T03:34:51Z","timestamp":1764992091000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmjopen.bmj.com\/lookup\/doi\/10.1136\/bmjopen-2023-080864"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12]]},"references-count":31,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2024,12,4]]},"published-print":{"date-parts":[[2024,12]]}},"alternative-id":["10.1136\/bmjopen-2023-080864"],"URL":"https:\/\/doi.org\/10.1136\/bmjopen-2023-080864","relation":{},"ISSN":["2044-6055","2044-6055"],"issn-type":[{"value":"2044-6055","type":"print"},{"value":"2044-6055","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,12]]}}}